AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal extract concentration 3
Description: Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal extract concentration 3
Description: Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thicken up clear concentration 1
Description: Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thicken up clear concentration 1
Description: Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thicken up clear concentration 2
Description: Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thicken up clear concentration 2
Description: Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thicken up clear concentration 3
Description: Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thicken up clear concentration 3
Description: Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study NCT01403610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 preoperative
Description: TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
Study NCT01403610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
Study NCT01403610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 (escalating) with bevacizumab 10mg/kg
Description: Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2
Study NCT03171363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze-contingent feedback
Description: Participants will receive gaze-contingent feedback according to their viewing patterns
Study NCT05657886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half swaddle
Description: Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
Study NCT05657886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Description: The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
Study NCT02913235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene discontinuation group
Description: Discontinuation of regular oral hygiene for 10 days
Study NCT02207348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
Study NCT02970331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pefcalcitol ointment, 0.005%
Description: pefcalcitol ointment, 0.005%
Study NCT00004660 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT00004660 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Study NCT02391272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Study NCT00896051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV) 300 mg
Description: Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 300 mg by mouth following a meal each morning on Substudy Days -1 to 7.
Study NCT00896051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV) 400 mg
Description: Atazanavir (ATV) 400 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 400 mg by mouth following a meal each morning on Substudy Days -1 to 7.
Study NCT00896051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (rtv) 100 mg
Description: Ritonavir (rtv) 100 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take rtv 100 mg by mouth following a meal each morning on Substudy Days -1 to 7.
Study NCT00896051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)
Description: 2 investigator-selected NRTIs taken as specified in the individual product labels for 2 weeks during the Pre-Treatment Period followed by 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) taken as specified in the individual product label for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) mg taken as specified in the individual product label during the Substudy.
Study NCT00896051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR) 200 mg
Description: Etravirine (ETR) 200 mg taken twice daily as two 100-mg tablets following a meal (morning and evening) for at least the first two weeks of the 48-week Treatment Period. If participating in the optional substudy, participants will take ETR 200 mg twice daily as two 100-mg tablets following a meal each morning and evening on Substudy Days -1 to 7.
Study NCT00896051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Description: Tenofovir disoproxil fumarate (TDF) 300 mg taken by mouth following a meal each morning on Substudy Days 1 to 7.
Study NCT04712331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graduated abdominal strengthening exercises
Description: Graduated abdominal strengthening exercises~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors).
Study NCT04712331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Russian current stimulation
Description: The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
Study NCT04712331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Product: Graduated abdominal strengthening exercises and the Russian current stimulation
Description: Graduated abdominal strengthening exercises and the Russian current stimulation~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors).~The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
Study NCT03030170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENDO GIA X-tra Thick reload with Tri Staple Technology
Description: Suture of the pancreas by normal stapling
Study NCT03030170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology
Description: Suture of the pancreas by reinforced stapling
Study NCT00622453 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: Electrocardiography Blood Test
Study NCT03569657 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A positive psychology workshop
Description: Group workshop
Study NCT00876928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: liquid vitamin D3 dissolved in medium chain triglyceride once a week
Study NCT00876928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: medium chain triglyceride given once per week
Study NCT03133754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DP-PEEP
Description: PEEP titration trial for the lowest DP after the alveolar recruitment maneuver
Study NCT03133754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RM-5
Description: Fixed standard PEEP after the alveolar recruitment maneuver
Study NCT00518791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Care
Description: A comprehensive individualised assessment by a dedicated multidisciplinary team (Multidisciplinary Assessment Center) and subsequent treatment by specifically trained health professionals (ParkinsonNet).
Study NCT00518791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: No altered organisation of care
Study NCT00044538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY59-8862 (Cytotoxic Taxane)
Description: Intravenous dose over 60 minutes every 3 weeks
Study NCT02245672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device
Study NCT02245672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device
Study NCT02245672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via the CRC749 and Diskus devices
Study NCT00947557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutogliptin
Description: Dutogliptin oral administration once daily on background of glimepiride with or without metformin
Study NCT00947557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral administration once daily on background of glimepiride with or without metformin
Study NCT03924739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated integrated care model for AF
Description: Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model comprising the following care components intended to comprehensively address the needs of AF patients: 1) a risk profile assessment and shared decision-making regarding OAC use; 2) an empowerment-based educational module on AF self-care; 3) nurse-initiated telephone support; and 4) patient-initiated contact for professional advice.
Study NCT04648735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: driving evaluation and practice
Description: The participants completed the actual driving with a licensed driving instructor on the passenger side in the car and with a dual-control, automatic-transmission car.~Each participant completed three runs of the same route. The first twos were practices to familiarize themselves with the course. The driving instructor graded them on the third run. Each trial took about 10 minutes. The participants were scored according to governmental driver test guidelines. Scoring on individual driving maneuver is weighted. Depending on the type of error, 8, 16 or 32 points were deducted from 100, for example, 32 points for getting too close to pedestrian lane, running a red light or railroad crossing, and 8 points for stopping in S-curve forward and backward. 70 or above is considered as a pass. The occupational therapists in the backseat recorded driving behaviors, including whether the driver checked rear and side mirrors, excessive sweating, distractibility, number of adjustments, etc.
Study NCT04648735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: driving evaluation and practice
Description: The participants completed the actual driving with a licensed driving instructor on the passenger side in the car and with a dual-control, automatic-transmission car.~Each participant completed three runs of the same route. The first twos were practices to familiarize themselves with the course. The driving instructor graded them on the third run. Each trial took about 10 minutes. The participants were scored according to governmental driver test guidelines. Scoring on individual driving maneuver is weighted. Depending on the type of error, 8, 16 or 32 points were deducted from 100, for example, 32 points for getting too close to pedestrian lane, running a red light or railroad crossing, and 8 points for stopping in S-curve forward and backward. 70 or above is considered as a pass. The occupational therapists in the backseat recorded driving behaviors, including whether the driver checked rear and side mirrors, excessive sweating, distractibility, number of adjustments, etc.
Study NCT01657955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride Injection
Study NCT01657955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Study NCT03975738 — intervention group
Intervention type: OTHER
Intervention: To be part of a blog
Description: To be part of a blog - to respond to questions and free to comment on other participants comments
Study NCT04398420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVERP
Description: Transurethral Vapor Enucleation Resection of the prostate
Study NCT04398420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TURis
Description: Transurethral Vapor Enucleation Resection of the prostate
Study NCT04398420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HoLEP
Description: Transurethral Vapor Enucleation Resection of the prostate
Study NCT04166890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine / EPINEPHrine Cartridge
Description: The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
Study NCT04166890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine / EPINEPHrine Cartridge
Description: The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
Study NCT03613441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs)
Description: Please refer to arm description
Study NCT01894633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the Chloroquine plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days
Study NCT01894633 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total brain radiotherapy
Description: 30 Gy in 10 daily fractions from Monday to Friday
Study NCT01894633 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Total brain radiotherapy
Description: 30 Gy in 10 daily fractions from Monday to Friday
Study NCT01305525 — intervention group
Intervention type: DEVICE
Intervention: St. Jude Medical Spinal Cord Stimulation Systems
Description: Spinal cord stimulation
Study NCT01097785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 40 mg, P.O.,daily for 30 days
Study NCT01097785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 30 days
Study NCT04357860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]
Description: Best available treatment up to 14 days plus Sarilumab 200 mg
Study NCT04357860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]
Description: Best available treatment up to 14 days plus Sarilumab 400 mg
Study NCT04357860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best available treatment
Description: Best available treatment up to 14 days
Study NCT03125525 — intervention group
Intervention type: DEVICE
Intervention: Cefaly device
Description: Use of Cefaly based upon the protocol of the approval study of the device, in which it is used once every day on the migraine prevention program
Study NCT00728715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide-formoterol single inhaler
Description: High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid
Study NCT00728715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide-formoterol single inhaler
Description: High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid
Study NCT00728715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of budesonide
Description: 1600 mcg/d of budesonide
Study NCT00728715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose of budesonide
Description: 1600 mcg/d of budesonide
Study NCT00728715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: medium dose of budesonide-formoterol
Study NCT00728715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B
Description: High Dose Inhaled Budesonide
Study NCT02898844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed Diet Condition
Description: One roommate dieted and the other ate normally.
Study NCT02898844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Both Diet Condition
Description: Both roommates dieted.
Study NCT02358382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pH Stat
Description: pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
Study NCT00639912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/Kg/hour for 12 hours.
Study NCT00639912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours